IRIS - Res&Arch Institutional Research Information System - Research & Archive

LIBERATI, Anna Marina
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.018
EU - Europa 9.134
AS - Asia 8.028
SA - Sud America 1.992
AF - Africa 234
OC - Oceania 36
Continente sconosciuto - Info sul continente non disponibili 23
Totale 30.465
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.798
SG - Singapore 3.791
IE - Irlanda 1.699
BR - Brasile 1.578
RU - Federazione Russa 1.499
UA - Ucraina 1.401
IT - Italia 1.165
VN - Vietnam 1.121
SE - Svezia 1.033
HK - Hong Kong 968
CN - Cina 926
DE - Germania 584
FR - Francia 553
FI - Finlandia 544
GB - Regno Unito 232
IN - India 198
BD - Bangladesh 160
KR - Corea 131
AR - Argentina 127
TR - Turchia 117
IQ - Iraq 101
AT - Austria 95
MX - Messico 89
CA - Canada 75
PK - Pakistan 72
UZ - Uzbekistan 70
CH - Svizzera 67
ZA - Sudafrica 65
EC - Ecuador 64
CO - Colombia 58
ID - Indonesia 56
PL - Polonia 53
NL - Olanda 48
CL - Cile 43
MA - Marocco 42
PH - Filippine 41
VE - Venezuela 41
SA - Arabia Saudita 39
JP - Giappone 37
AU - Australia 33
PY - Paraguay 29
ES - Italia 28
TN - Tunisia 28
LB - Libano 27
PE - Perù 27
RO - Romania 25
MY - Malesia 23
KE - Kenya 22
GR - Grecia 19
CZ - Repubblica Ceca 18
EU - Europa 18
BE - Belgio 17
BO - Bolivia 17
AE - Emirati Arabi Uniti 15
EG - Egitto 15
NP - Nepal 15
ET - Etiopia 14
IL - Israele 14
JO - Giordania 14
DZ - Algeria 11
JM - Giamaica 11
KZ - Kazakistan 10
PS - Palestinian Territory 9
AZ - Azerbaigian 8
OM - Oman 8
TH - Thailandia 8
AL - Albania 7
MD - Moldavia 7
UY - Uruguay 7
BB - Barbados 6
DO - Repubblica Dominicana 6
HN - Honduras 6
SN - Senegal 6
SY - Repubblica araba siriana 6
TW - Taiwan 6
BG - Bulgaria 5
CR - Costa Rica 5
KG - Kirghizistan 5
LT - Lituania 5
PA - Panama 5
SK - Slovacchia (Repubblica Slovacca) 5
XK - ???statistics.table.value.countryCode.XK??? 5
AO - Angola 4
RS - Serbia 4
BA - Bosnia-Erzegovina 3
BH - Bahrain 3
CI - Costa d'Avorio 3
GA - Gabon 3
GE - Georgia 3
GT - Guatemala 3
IR - Iran 3
KH - Cambogia 3
KW - Kuwait 3
ML - Mali 3
MM - Myanmar 3
NI - Nicaragua 3
PT - Portogallo 3
QA - Qatar 3
SI - Slovenia 3
TT - Trinidad e Tobago 3
Totale 30.412
Salva come PNG Salva come JPEG
Città #
Singapore 2.492
Dublin 1.697
Chandler 1.371
San Mateo 1.079
Hong Kong 958
San Jose 786
Dong Ket 667
Boardman 626
Ashburn 603
Moscow 528
Santa Clara 512
Altamura 491
Medford 479
Princeton 478
Lauterbourg 406
Wilmington 406
Lawrence 371
Andover 351
Jacksonville 314
Perugia 253
Ann Arbor 210
Ho Chi Minh City 160
Des Moines 145
Beijing 143
The Dalles 143
Saint Petersburg 136
Seoul 123
São Paulo 119
Norwalk 95
Los Angeles 91
Hanoi 90
Falls Church 69
Helsinki 66
New York 64
San Paolo di Civitate 64
Munich 61
Izmir 50
Houston 49
Rio de Janeiro 48
Shanghai 48
Piscataway 47
Woodbridge 47
Vienna 43
Belo Horizonte 41
Nuremberg 38
Baghdad 36
Orem 35
Frankfurt am Main 34
Tokyo 32
Chennai 29
Brasília 28
Guangzhou 28
Tashkent 28
Dhaka 27
Porto Alegre 27
Warsaw 27
Johannesburg 25
Curitiba 24
Haiphong 24
Guayaquil 23
Rome 22
Santiago 22
Turku 22
Campinas 21
Chicago 21
Brooklyn 20
London 20
Mumbai 20
Redwood City 20
Dallas 19
Dearborn 19
Denver 19
Istanbul 19
Jeddah 19
Lahore 19
Cape Town 18
Den Haag 18
Lima 18
Quito 18
Salvador 18
Brussels 17
Frankfurt Am Main 17
Redmond 17
Caracas 16
Manchester 16
Montreal 16
Nairobi 16
Phoenix 16
Port Pirie 16
Amsterdam 15
Ankara 15
Columbus 15
Goiânia 15
New Delhi 15
Stockholm 15
Toronto 15
Atlanta 14
Council Bluffs 14
Jakarta 14
Medellín 14
Totale 18.185
Salva come PNG Salva come JPEG
Nome #
Integration of Traditional and Western Medicine in Vietnamese Populations: A Review of Health Perceptions and Therapies 169
WEEKLY CARFILZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (WKCYD) FOLLOWED BY MAINTENANCE WITH WEEKLY CARFILZOMIB (WK) IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) 157
[Metastatic gastric cancer successfully treated with surgery and chemotherapy. Case report]. 156
Artocarpus tonkinensis protects mice against collagen-induced arthritis and decreases Th17 cell function 152
Anti-cancer activity of compounds isolated from Bursera microphylla 149
Anti-rheumatoid arthritis activity of decoction from the leaves of the tree Artocarpus tonkinensis used in Vietnamese traditional medicine 148
67Ga scan detects residual active disease and it is predictive of disease-free survival in malignant lymphoma patients 147
Maesopsin 4-O-D-glucoside, a natural compound isolated from the leaves of Artocarpus tonkinensis, inhibits proliferation and up-regulates HMOX1, SRXN! and BCAS3 in acute myeloid leukemia 144
Anti-cancer activity of compounds isolated from Bursera microphylla. 140
67Ga scan detects residual active disease and it is predictive of disease-free survival in malignant lymphoma patients. 135
67Ga-scan detects residual active disease and it is predictive of disease-free survival in classical Hodgkin's disease patients 133
Occurrence of the same chromosome abnormalities in Ph+ and Ph- cells in chronic myeloid leukaemia. Evidence of a secondary origin of the Ph chromosome? 129
Monitoring treatment and survival in chronic myeloid leukemia. 124
A 4-day chemosensitivity assay in vitro reliably predicts clinical response of patients with acute leukemia 124
R-CHOP vs R-miniCEOP for the initial treatment of elderly “fit“ patients with diffuse large B-cell lymphoma. Results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi (IIL) 120
SUMO proteins: Guardians of immune system 119
ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned 118
Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma. 118
Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi. 117
67Ga-scan usefulness in predicting the clinical outcome and the long-term effects of chemotherapy in lymphoma patients 116
67Ga-SPECT/CT with a hybrid system in the clinical management of lymphoma 115
A case of acute myeloid leukemia with deletion of chromosome 7 following PBSC transplantation. 114
Evaluation of response to therapy with 67Ga scintigraphy, CT scan and magnetic resonance in malignant lymphomas. 113
Prognosi e terapia del mieloma multiplo. 112
Bcl-xL overexpression decreases GILZ levels and inhibits glucocorticoid-induced activation of caspase-8 and caspase-3 in mouse thymocytes 111
The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up. 110
Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first-line therapy in high-risk diffuse large-cell lymphoma. 109
Pharmacological modulation of caspase-8 in thymus-related medical conditions. 109
Role of microRNAs in the activity of new therapeutic inhibitors of Src kinases in CD133+ colorectal cancer cells 108
Natural-killer-stimulatory effect of combined low-dose interleukin-2 and interferon beta in hairy-cell leukemia patients. 107
Rare immunological presentation in B-cell chronic lymphocytic leukaemia. 106
A continous recurrent course in a case of nodular-sclerosis (NS) classical Hodgkin's lymphoma (cHL) associated with Castleman's disease (CD) 105
Antibodies binding granulocyte-macrophage colony stimulating factor produced by cord blood-derived B cell lines immortalized by Epstein-Barr virus in vitro. 105
All-trans-retinoic acid (ATRA) in patients with chronic myeloid leukemia in the chronic phase. 105
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients 103
Addition of rituximabto dose-denseand high dose chemotherapy with autologous transplantation in untreated poor-prognosis diffuse large B-cell lymphoma: Results of phase II trial 103
Bortezomib plus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 Trial. 103
Lenalidomide and its role in the management of multiple myeloma. 103
Could thymomectomy be a reasonable option for non-myasthenic thymoma patients? 103
Alfa-interferon in the treatment of essential thrombocythemia: clinical results and evaluation of its biological effects on the hematopoietic neoplastic clone. 102
Fusarubin and anhydrofusarubin isolated from a Cladosporium species inhibit cell growth in human cancer cell lines 102
L'interferone alfa nella leucemia mieloide cronica 101
Anagrelide in essential thrombocythemia: a retrospective analysis of 220 patients 101
GM-CSF: clinical trials in non-Hodgkin's lymphoma patients with chemotherapy induced leucopenia. 100
Isolation and identification of bioactive molecules from resins used in traditional medicine: Commiphora erythraea and Bursera microphylla 100
Complex translocations of the Ph chromosome and Ph-negative CML arise from similar mechanisms as evidenced by FISH analysis. 100
Cell membrane markers and phytohemagglutinin reactivity of circulating lymphocytes from chronic myelocytic leukemia patients. 99
The role of autotransplantation in chronic lymphocytic leukemia and results from the italian group. 97
Myelomonocytic-associated antigens in a case of genotypically, phenotypically and functionally B-cell lymphoma. 97
A brief course of chemo-immunotherapy FND plus rituximab is effective to induce a high clinical and molecular response in elderly patients with advanced stage follicular lymphoma (FL) at diagnosis. 96
Effectiveness and Safety of Combined Cytoreductive Therapy In 56 Patients With Essential Thrombocythaemia: Report of the Registro Italiano Trombocitemie (rit) 96
Melphalan 200 mg/m2 versus Melphalan 100 mg/m2 in newly diagnosed myeloma patients: a prospective, multi-center phase III study. 95
Osimertinib 95
La scintigrafia ossea nella diagnosi e nel "follow-up" del carcinoma mammario. 94
Indicazione all’autotrapianto in prima linea nel linfoma non-Hodgkin’s aggressivo. 93
5-Fluorouracil, vincristine and hydroxyurea combination chemotherapy in metastatic colorectal cancer. 93
Phase I-II trial on natural beta interferon in chemoresistant and relapsing multiple myeloma. 92
Fattori prognostici nel carcinoma colon-retto. 92
Pharmacologic and immunologic effects of human leukocyte interferons in patients with neoplasia: an interim report. 91
The Hexane Fraction of Bursera microphylla A Gray Induces p21-Mediated Antiproliferative and Proapoptotic Effects in Human Cancer-Derived Cell Lines 91
Preliminary results of prophylactic HIPEC in patients with locally advanced gastric cancer. 91
In vitro synergistic activity of PDN-IFN alpha and NM + IFN alpha combinations on fresh bone-marrow samples from multiple myeloma patients. 90
Rapid and sustained response of an intra- and extracranial large cell lymphoma mass to liposomal intrathecal Ara-C and R-MegaCEOP systemic chemotherapy. 90
Long term outcome of Ph plus CML patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib era. 90
Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma 90
Ph '-positive (Ph '+) chronic myeloid leukemia (CML) presenting as Ph ' plus T-lymphoblastic lymphoma (LL) resistant to high-dose chemotherapy and Gleevec. 89
Pre-autologous stem cell transplantation (ASCT) treatment with rituximab does not impair stem cell harvest and engraftment in untreated patients with diffuse large B-cell lymphoma (B-DLCL) at poor prognosis 89
Interferon Alpha-2b as therapy for Ph'-positive chronic myelogenous leukemia. A study of 82 patients treated with intermittent administration. 89
High dose sequential chemotherapy with autologous transplantation versus dose-dense chemotherapy MegaCEOP as first line treatment in poor-prognosis diffuse large cell lymphoma: an "Intergruppo Italiano Linfomi" randomized trial. 89
A continous recurrent course in a case of nodular-sclerosis (NS) classical Hodgkin's lymphoma (cHL) associated with Castleman's disease (CD) 89
Imatinib and pegylated human recombinat interferon-alpha2b in early chronic phase chronic myeloid leukaemia. 89
Conventional induction treatments do not influence overall survival in multiple myeloma. 88
A phase I study of human natural interferon-beta in cancer patients. 88
The therapeutic effect of new Src inhibitor in colon cancer cells and potential role of mir494. 88
Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study 88
Interferon-alpha-2b as therapy for untreated and pretreated patients with Ph' positive chronic myeloid leukemia 87
Role of caspase-8 in thymus function 87
Chronic myeloid leukemia, BCR/ABL transcript, response to alpha-interferon and survival. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. 87
Immunologic profile in patients with Hodgkin's disease in complete remission. 86
Staging of chronic myeloid leukaemia. 86
R-CHOP vs R-MiniCEOP in elderly patients with diffuse large B-cell lymphoma (B-DLCL) prospectively selected by a multidimensional evaluation scale: Preliminary results of a Randomized study performed by Intergruppo Italiano Linfomi (IIL) 86
Sustained molecular remissions are achievable with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia and additional cytogenetic clonal evolution 84
Treatment of Ph-positive Chronic Myeloid Leukemia with alpha-Interferon (Roferon-A). The Italian Cooperative Study Group experience. 84
L’approccio terapeutico nell’anziano con mielodisplasia. 84
Effect of adding Rituximab to intensified and high dose chemotherapy(HDC)with ASCT as first line treatment in stage III-IV at intermediate-high (IH) and high risk (HR) diffuse large B-cell lymphoma 83
Neutrophilic-chronic myeloid leukemia: Low levels of p230 BCR/ABL mRNA and undetectable p230 BCR/ABL protein may predict an indolent course 83
Combination chemotherapy with 5-fluorouracil and methyl-CCNU for the treatment of advanced gastrointestinal cancer. 83
Citotossicità spontanea in pazienti con B-LLC. 82
Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase III trial. 82
A prospective randomized trial of oral melphalan, prednisone, thalidomide (MPT) vs oral melphalan, prednisone (MP): An interim analysis. 82
A Phase III Study of Enoxaparin vs Aspirin vs Low-Dose Warfarin as Thromboprophylaxis for Newly Diagnosed Myeloma Patients Treated with Thalidomide Based-Regimens. 82
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma 82
Has 67Ga-scan a role in the evaluation of lymphoma response to conventional or high dose chemotherapy? 81
Has the 67Ga-SPET a role in monitoring Hodgkin and primary mediastinal lymphoma in the PET-FDG age? 81
Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. 80
Complete response correlates with long-term progression-free and overall survivals in elderly myeloma treated with novel agents: analysis of 1175 patients 80
A Phase Iii Study of Enoxaparin Versus Aspirin Versus Low-dose Warfarin As Thromboprophylaxis For Patients With Newly Diagnosed Multiple Myeloma Treated Up-front With Thalidomide Based-regimens 80
Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma. 79
Evaluation of response therapy with 67Ga scintigraphy, CT scan and magnetic resonance in malignant lymphomas. 79
Expression of Met Mrna As Prognostic Marker In Multiple Myeloma Patients Treated With Novel Drugs 79
Totale 10.192
Salva come PNG Salva come JPEG
Categoria #
all - tutte 150.752
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 150.752
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.017 0 0 0 0 0 0 0 0 0 108 169 740
2021/20223.652 63 696 57 123 125 55 63 1.377 39 67 385 602
2022/20235.594 512 1.044 31 395 402 609 7 253 2.147 6 151 37
2023/20241.834 137 213 107 32 20 15 555 26 80 67 244 338
2024/20254.349 47 548 89 125 569 119 102 384 1.167 357 492 350
2025/20269.532 631 670 795 1.427 890 800 1.691 639 1.210 779 0 0
Totale 31.731